Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study - Summary - MDSpire
Advertisement
Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study
To develop and validate a nomogram that assists in determining the necessity of systematic biopsy (SBx) in conjunction with MRI-targeted biopsy (TBx) for men with suspicious prostate MRI findings.
Key Findings:
MRI-targeted biopsy (TBx) is superior to systematic biopsy (SBx) in detecting clinically significant prostate cancer, suggesting a shift in diagnostic strategy.
Omitting SBx may miss approximately 16% of csPCa in biopsy-naive patients, highlighting the need for careful consideration in clinical practice.
The developed nomogram can aid clinicians in deciding when SBx is necessary alongside TBx, potentially improving patient outcomes.
Interpretation:
The study supports the use of TBx as the primary method for prostate cancer diagnosis, with a nomogram that provides a structured approach to guide the decision for additional SBx based on MRI findings, enhancing clinical decision-making.
Limitations:
The accuracy of the nomogram requires further validation in larger, more diverse populations to ensure its generalizability.
Potential biases from retrospective data analysis may affect the reliability of the findings and should be considered when interpreting results.
Conclusion:
The integration of a nomogram based on MRI volumetric parameters may optimize biopsy strategies, reducing unnecessary procedures while ensuring that significant cancers are not missed, thus improving patient care.
by Ugo Falagario, Ivan Jambor, Pekka Taimen, Kari T. Syvänen, Esa Kähkönen, Harri Merisaari, Ileana Montoya Perez, Juha Knaapila, Aida Steiner, Janne Verho, Ashutosh Tewari, Hannu J. Aronen, Giuseppe Carrieri, Peter J. Boström, Otto Ettala
